Nivolumab for the treatment of colorectal cancer

References

• Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017 May 06;67:177–193. PubMed PMID: 28248415.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017 Jan;67:7–30. PubMed PMID: 28055103.
   PubMed Web of Science ®Google Scholar
• deBraud F, Munzone E, Nole F, et al. Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil. Am J Clin Oncol. 1998 Jun;21:279–283. PubMed PMID: 9626798.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998 Oct 31;352:1413–1418. PubMed PMID: 9807987.
   PubMed Web of Science ®Google Scholar
• Kohne CH, van Cutsem E, Wils J, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol. 2005 Aug 1;23:4856–4865. PubMed PMID: 15939923.
   PubMed Web of Science ®Google Scholar
• Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000 Sep 28;343:905–914. PubMed PMID: 11006366.
   PubMed Web of Science ®Google Scholar
• Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000 Mar;25(355):1041–1047. PubMed PMID: 10744089.
   Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3;350:2335–2342. PubMed PMID: 15175435.
   PubMed Web of Science ®Google Scholar
• Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008 May 10;26:2311–2319. PubMed PMID: 18390971.
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007 Nov 15;357:2040–2048. PubMed PMID: 18003960.
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Tebbutt NC, Kabbinavar F, et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist. 2013;18:1004–1012. PubMed PMID: 23881988; PubMed Central PMCID: PMCPMC3780632.
   PubMed Web of Science ®Google Scholar
• de la Chapelle A, Hampel H. Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol. 2010 Jul 10;28:3380–3387.
   PubMed Web of Science ®Google Scholar
• de Weger VA, Turksma AW, Voorham QJ, et al. Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer. Clin Cancer Res. 2012 Feb 01;18:882–889. 10.1158/1078-0432.CCR-11-1716. PubMed PMID: 22156611.
   PubMed Web of Science ®Google Scholar
• Takemoto N, Konishi F, Yamashita K, et al. The correlation of microsatellite instability and tumor-infiltrating lymphocytes in hereditary non-polyposis colorectal cancer (HNPCC) and sporadic colorectal cancers: the significance of different types of lymphocyte infiltration. Jpn J Clin Oncol. 2004 Feb;34:90–98. PubMed PMID: 15067103.
   PubMed Web of Science ®Google Scholar
• Scarpa M, Ruffolo C, Canal F, et al. Mismatch repair gene defects in sporadic colorectal cancer enhance immune surveillance. Oncotarget. 2015 Dec 22;6:43472–43482. PubMed PMID: 26496037; PubMed Central PMCID: PMCPMC4791244.
   PubMed Web of Science ®Google Scholar
• Goldstein J, Tran B, Ensor J, et al. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol. 2014 May;25:1032–1038. PubMed PMID: 24585723; PubMed Central PMCID: PMCPMC4072907.
   PubMed Web of Science ®Google Scholar
• Lothe RA, Peltomaki P, Meling GI, et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res. 1993 Dec;15(53):5849–5852. PubMed PMID: 8261392.
   Google Scholar
• Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010 Jul 10;28:3219–3226. PubMed PMID: 20498393; PubMed Central PMCID: PMCPMC2903323.
   PubMed Web of Science ®Google Scholar
• Copija A, Waniczek D, Witkos A, et al. Clinical significance and prognostic relevance of microsatellite instability in sporadic colorectal cancer patients. Int J Mol Sci. 2017 Jan 6;18. PubMed PMID: 28067827; PubMed Central PMCID: PMCPMC5297741.
   PubMed Web of Science ®Google Scholar
• Vinay DS, Ryan EP, Pawelec G, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015 Dec;35(Suppl):S185–S198. PubMed PMID: 25818339.
   PubMed Web of Science ®Google Scholar
• Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006;90:51–81. PubMed PMID: 16730261.
   PubMed Web of Science ®Google Scholar
• Morse MA, Chaudhry A, Gabitzsch ES, et al. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol Immunother. 2013 Aug;62:1293–1301. PubMed PMID: 23624851; PubMed Central PMCID: PMCPMC3732790.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Lenz HJ, Marshall J, et al. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin Cancer Res. 2008 Aug 01;14:4843–4849. PubMed PMID: 18676757.
   PubMed Web of Science ®Google Scholar
• Liu KJ, Wang CC, Chen LT, et al. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res. 2004 Apr;15(10):2645–2651. PubMed PMID: 15102666.
   Google Scholar
• Nair SK, Morse M, Boczkowski D, et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg. 2002 Apr;235:540–549. PubMed PMID: 11923611; PubMed Central PMCID: PMCPMC1422470.
   PubMed Web of Science ®Google Scholar
• Schulze T, Kemmner W, Weitz J, et al. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol Immunother. 2009 Jan;58:61–69. PubMed PMID: 18488223.
   PubMed Web of Science ®Google Scholar
• Chung KY, Gore I, Fong L, et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol. 2010 Jul 20;28:3485–3490. PubMed PMID: 20498386.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015 Jun 25;372:2509–2520.
   PubMed Web of Science ®Google Scholar
• Safi Shahda AMN, Bekaii-Saab TS, O’Neil BH, et al. A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer. Journal of Clinical Oncology. 2017;35(15_suppl):3541.
   Google Scholar
• Bendell JC, Powderly JD, Lieu CH, et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 2015;33(3_suppl):704.
   Google Scholar
• Liu L, Mayes PA, Eastman S, et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res. 2015 Apr 1;21:1639–1651.
   PubMed Web of Science ®Google Scholar
• Bendell JC, Bang Y-J, Chee CE, et al. A phase 1b study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 2018;36(Suppl4S):560.
   Google Scholar
• Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014 Sep;2:846–856. PubMed PMID: 24872026.
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015 Jan 22;372:320–330. PubMed PMID: 25399552.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366:2443–2454.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010 Jul 01;28:3167–3175. PubMed PMID: 20516446; PubMed Central PMCID: PMCPMC4834717.
   PubMed Web of Science ®Google Scholar
• Bajaj G, Wang X, Agrawal S, et al. Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. CPT Pharmacometrics Syst Pharmacol. 2017;6(Jan):58–66. PubMed PMID: 28019091; PubMed Central PMCID: PMCPMC5270302.
   PubMedGoogle Scholar
• Bristol-Myers Squibb Nivolumab Prescribing Information. Opdivo (Nivolumab). Princeton (NJ)  Bristol Myer Squibb; 2018.
   Google Scholar
• Zhao X, Suryawanshi S, Hruska M, et al. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. Ann Oncol. 2017 Aug 1;28:2002–2008. PubMed PMID: 28520840.
   PubMed Web of Science ®Google Scholar
• Zhao X, Ivaturi V, Gopalakrishnan M, et al. A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4 weeklys (Q4W) dosing schedule across multiple tumor types. Cancer Res. 2017;77(13 Suppl). AACR.
   Google Scholar
• Lipson EJ, Sharfman WH, Drake CG, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2013 Jan 15;19(2):462–468. 10.1158/1078-0432.CCR-12-2625. PubMed PMID: 23169436; PubMed Central PMCID: PMCPMC3548952.
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Nokihara H, Yamada Y, et al. Phase I study of nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. Invest New Drugs. 2017 Apr;35:207–216. 10.1007/s10637-016-0411-2. PubMed PMID: 27928714; PubMed Central PMCID: PMCPMC5352798.
   PubMed Web of Science ®Google Scholar
• Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017 Sep;18:1182–1191. PubMed PMID: 28734759..
   PubMed Web of Science ®Google Scholar
• Overman MJ, McDermott RS, Aglietta M, et al. Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): long-term survival according to prior line of treatment from CheckMate-142. Journal of Clinical Oncology. 2018;36(4_suppl):554.
   PubMedGoogle Scholar
• Overman MJ, McDermott RS, Leach J, et al. Nivolumab ± Ipiliumumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instablity: checkmate 142 interim results. J Clin Oncol. 2016;3501(15_suppl).
   Google Scholar
• Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018 Jan 20:JCO2017769901. PubMed PMID: 29355075. Doi:10.1200/JCO.2017.76.9901
   PubMedGoogle Scholar
• Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015 Dec;26:2375–2391. PubMed PMID: 26371282.
   PubMed Web of Science ®Google Scholar
• Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl_4):iv119–iv142. PubMed PMID: 28881921.
   PubMedGoogle Scholar
• Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015 Sep 24;373:1270–1271. 10.1056/NEJMc1509660. PubMed PMID: 26398076.
   PubMed Web of Science ®Google Scholar
• Friedman CF, Navid-Azarbaijani P, Shoushtari AN, et al. Toxicity associated with ipilimumab and nivolumab combination thearpy in melanoma patients treated at a single-instituion under an expanded access program. Journal of Clinical Oncology. 2016;34.
   Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015 Nov 5;373:1803–1813. PubMed PMID: 26406148; PubMed Central PMCID: PMCPMC5719487.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015 Jul 9;373:123–135. PubMed PMID: 26028407; PubMed Central PMCID: PMCPMC4681400.
   PubMed Web of Science ®Google Scholar
• Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II checkMate 205 trial. J Clin Oncol. 2018 May 10;36:1428–1439. PubMed PMID: 29584546.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G Jr., Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016 Nov 10;375:1856–1867. PubMed PMID: 27718784; PubMed Central PMCID: PMCPMC5564292.
   PubMed Web of Science ®Google Scholar
• Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar;18:312–322. PubMed PMID: 28131785.
   PubMed Web of Science ®Google Scholar
• Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015 Apr;16(4):375–384. PubMed PMID: 25795410.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22;373:1627–1639. PubMed PMID: 26412456; PubMed Central PMCID: PMCPMC5705936.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017 Jun 24;389:2492–2502. PubMed PMID: 28434648.
   PubMed Web of Science ®Google Scholar
• Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016 Sep;17:1283–1294. PubMed PMID: 27451390; PubMed Central PMCID: PMCPMC5541855.
   PubMed Web of Science ®Google Scholar